Group 1 - The core point of the news is that Zhaoyan New Drug's stock price increased by 5.08% to 37.68 CNY per share, with a trading volume of 424 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 28.235 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs, with its main business revenue composition being 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] - The company was established on February 25, 1998, and went public on August 25, 2017, located in Beijing Economic and Technological Development Zone [1] Group 2 - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 2.1693 million shares in the third quarter, now holding 12.4838 million shares, which accounts for 1.67% of the circulating shares [2] - The estimated floating profit from Huabao CSI Medical ETF's investment in Zhaoyan New Drug is approximately 22.7206 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 25.263 billion CNY, yielding 2.53% this year and 12.04% over the past year [2]

Group 1 - The core viewpoint of the news is that Tongce Medical's stock has increased by 5%, reaching a price of 48.30 yuan per share, with a trading volume of 481 million yuan and a turnover rate of 2.25%, resulting in a total market capitalization of 21.604 billion yuan [1] - Tongce Medical Co., Ltd. is located in Hangzhou, established on August 30, 1995, and listed on October 30, 1996. The company's main business involves medical service investment and dental medical services [1] - The revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales 4.06%, construction engineering 2.72%, and others 0.38% [1] Group 2 - From the perspective of the top ten circulating shareholders of Tongce Medical, Huabao Fund holds a position in the top ten shareholders, with the Huabao CSI Medical ETF (512170) reducing its holdings by 1.5804 million shares in the third quarter, now holding 8.8854 million shares, which represents 1.99% of the circulating shares [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 25.263 billion yuan. Year-to-date return is 4.77%, ranking 2834 out of 5579 in its category; the one-year return is 14.49%, ranking 3655 out of 4285; and since inception, the return is 6.66% [2] - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a cumulative tenure of 13 years and 113 days, with the total asset scale of 101.358 billion yuan. The best fund return during his tenure is 162.35%, while the worst is -98.01% [2]

Group 1 - The core point of the news is that Nanwei Medical experienced a decline of 5.04% in its stock price, reaching 81.18 yuan per share, with a trading volume of 112 million yuan and a turnover rate of 0.72%, resulting in a total market capitalization of 15.249 billion yuan [1] - Nanwei Medical Technology Co., Ltd. is located in Jiangbei New District, Nanjing, Jiangsu Province, and was established on May 10, 2000, with its listing date on July 22, 2019. The company's main business involves the research, development, manufacturing, and sales of minimally invasive medical devices [1] - The revenue composition of Nanwei Medical is as follows: endoscopic consumables account for 77.80%, other categories 13.17%, tumor intervention 7.28%, visualization 1.00%, and other (supplementary) 0.74% [1] Group 2 - From the perspective of the top ten circulating shareholders of Nanwei Medical, Huabao Fund has one fund among them. The Huabao CSI Medical ETF (512170) reduced its holdings by 459,000 shares in the third quarter, holding a total of 3.2232 million shares, which represents 1.72% of the circulating shares. The estimated floating loss today is approximately 13.8921 million yuan [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a latest scale of 25.263 billion yuan. Year-to-date returns are 9.07%, ranking 2041 out of 5579 in its category; the one-year return is 19.46%, ranking 3487 out of 4270; and since inception, the return is 11.04% [2]

Group 1 - The core viewpoint of the news is that Tongce Medical's stock has seen a significant increase of 5.19%, reaching a price of 46.60 yuan per share, with a trading volume of 570 million yuan and a turnover rate of 2.80%, resulting in a total market capitalization of 20.844 billion yuan [1] - Tongce Medical Co., Ltd. is located in Hangzhou, established on August 30, 1995, and listed on October 30, 1996. The company's main business involves medical service investment and dental medical services [1] - The revenue composition of Tongce Medical is as follows: medical services account for 92.84%, product sales 4.06%, construction engineering 2.72%, and others 0.38% [1] Group 2 - From the perspective of the top ten circulating shareholders of Tongce Medical, Huabao Fund's ETF, Huabao Zhongzheng Medical ETF (512170), reduced its holdings by 1.5804 million shares in the third quarter, now holding 8.8854 million shares, which represents 1.99% of the circulating shares [2] - The Huabao Zhongzheng Medical ETF (512170) was established on May 20, 2019, with a latest scale of 26.404 billion yuan. Year-to-date returns are 7.98%, ranking 1481 out of 5542 in its category; the one-year return is 16.76%, ranking 3551 out of 4243; and since inception, the return is 9.93% [2] - The fund manager of Huabao Zhongzheng Medical ETF is Hu Jie, who has a cumulative tenure of 13 years and 101 days, with total fund assets of 100.204 billion yuan. The best fund return during his tenure is 165.65%, while the worst is -98.01% [2]

Group 1 - The core viewpoint of the news is that Aihuilong's stock price increased by 5.42% to 15.37 CNY per share, with a trading volume of 131 million CNY and a turnover rate of 1.54%, resulting in a total market capitalization of 8.782 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescent immunoassay methods [1] - The company's revenue composition includes: self-produced reagents (non-COVID products) 58.57%, self-produced consumables (non-COVID products) 12.60%, self-produced instruments (non-COVID products) 11.92%, agency reagents 11.02%, agency consumables 3.30%, other (supplementary) 1.89%, agency instruments 0.68%, and software services 0.04% [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 1.7669 million shares in the third quarter, holding a total of 9.6516 million shares, which represents 1.69% of the circulating shares [2] - The estimated floating profit for Huabao CSI Medical ETF today is approximately 7.6248 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a latest scale of 26.404 billion CNY, and has achieved a year-to-date return of 4.86%, ranking 207 out of 5490 in its category [2]

Company Overview - Microelectrophysiology, a company based in Shanghai, specializes in innovative medical devices for electrophysiological intervention and ablation therapy, with a total market capitalization of 11.285 billion yuan as of November 20 [1] - The company was established on August 31, 2010, and went public on August 31, 2022 [1] - Revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1] Stock Performance - On November 20, the stock price increased by 5.45%, reaching 23.98 yuan per share, with a trading volume of 63.1665 million yuan and a turnover rate of 2.19% [1] Shareholder Information - Huabao Fund's Huabao Zhongzheng Medical ETF (512170) is among the top ten circulating shareholders, having reduced its holdings by 574,900 shares in the third quarter, now holding 4.0374 million shares, which is 3.23% of the circulating shares [2] - The ETF has a current scale of 26.404 billion yuan and has achieved a year-to-date return of 8.3% [2] Fund Management - The fund manager of Huabao Zhongzheng Medical ETF is Hu Jie, who has a tenure of 13 years and 39 days, managing assets totaling 100.204 billion yuan [3] - The best fund return during Hu Jie's tenure is 183.07%, while the worst return is -98.01% [3]